Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes - PubMed (original) (raw)

Ira Driscoll 1 2 3, Catherine L Gallagher 4 5, Sterling C Johnson 1 2 4, Sanjay Asthana 1 2 4, Bruce P Hermann 1 2 5, Mark A Sager 1 2, Kaj Blennow 6 7, Henrik Zetterberg 6 7 8 9, Cynthia M Carlsson 1 2 4, Corinne D Engelman 1 2 10, Dena B Dubal 11, Ozioma C Okonkwo 1 2 4

Affiliations

Ira Driscoll et al. J Alzheimers Dis. 2021.

Erratum in

Abstract

Background: Identification of new genetic variants that modify Alzheimer's disease (AD) risk will elucidate novel targets for curbing the disease progression or delaying symptom onset.

Objective: To examine whether the functionally advantageous KLOTHO gene KL-VS variant attenuates age-related alteration in cerebrospinal fluid (CSF) biomarkers or cognitive function in middle-aged and older adults enriched for AD risk.

Methods: Sample included non-demented adults (N = 225, mean age = 63±8, 68% women) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center who were genotyped for KL-VS, underwent CSF sampling and had neuropsychological testing data available proximal to CSF draw. Covariate-adjusted multivariate regression examined relationships between age group (Younger versus Older; mean split at 63 years), AD biomarkers, and neuropsychological performance tapping memory and executive function, and whether these relationships differed between KL-VS non-carriers (KL-VSNC) and heterozygote (KL-VSHET).

Results: In the pooled analyses, older age was associated with higher levels of total tau (tTau), phosphorylated tau (pTau), and their respective ratios to amyloid-β (Aβ)42 (ps ≤ 0.002), and with poorer performance on neuropsychological tests (ps ≤ 0.001). In the stratified analyses, KL-VSNC exhibited this age-related pattern of associations with CSF biomarkers (all ps ≤ 0.001), and memory and executive function (ps ≤ 0.003), which were attenuated in KL-VSHET (ps ≥ 0.14).

Conclusion: Worse memory and executive function, and higher tau burden with age were attenuated in carriers of a functionally advantageous KLOTHO variant. KL-VS heterozygosity seems to be protective against age-related cognitive and biomolecular alterations that confer risk for AD.

Keywords: Alzheimer’s disease; biomarkers; cerebrospinal fluid; executive function; memory.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.. Age differentially associates with CSF tau measures as a function of KL-VS status.

Bar graphs depicting group differences (M(SE)) in tau between Younger (black) and Older (white) individuals. Among KL-VSNC, Older age was associated with worse levels of A) total tau (tTau), B) phosphorylated tau (pTau), and their respective ratios to Aβ42 (C & D). This age-related pattern of associations with CSF tau biomarkers was abated in KL-VSHET. Abbreviations: M=mean; SE=standard error; Aβ42 = β-amyloid42; tTau = total tau; pTau = phosphorylated tau; KL-VSNC = KL-VS non-carriers; KL-VSHET = KL-VS heterozygotes.

Figure 2.

Figure 2.. Age differentially associates with measures of episodic memory and executive function as a function of KL-VS status.

Bar graphs depicting group differences (M(SE)) in cognition between Younger (black) and Older (white) individuals. KL-VSNC exhibited age-related deficits in memory (A & B) and executive function (C & D), which were attenuated in KL-VSHET. Abbreviations: M=mean; SE=standard error; RAVLT = Rey Auditory Verbal Learning Test (total trials); TMT = Trail Making Test (time in seconds); KL-VSNC = KL-VS non-carriers; KL-VSHET = KL-VS heterozygotes.

Similar articles

Cited by

References

    1. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019;15:565–581. - PubMed
    1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14:367–429.
    1. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 2016;18:421. - PMC - PubMed
    1. Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging 2019;83:124–129. - PMC - PubMed
    1. Gallagher M, Okonkwo OC, Resnick SM, Jagust WJ, Benzinger TLS, Rapp PR. What are the threats to successful brain and cognitive aging? Neurobiol Aging 2019;83:130–134. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources